Company Description
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder.
The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.
Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
| Country | United States |
| Founded | 2006 |
| IPO Date | Apr 16, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Neil F. McFarlane |
Contact Details
Address: 1180 Celebration Boulevard, Suite 103 Celebration, Florida 34747 United States | |
| Phone | (321) 939-3416 |
| Website | zevra.com |
Stock Details
| Ticker Symbol | ZVRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434647 |
| ISIN Number | US4884452065 |
| Employer ID | 20-5894398 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil F. McFarlane | President, Chief Executive Officer and Director |
| Christal M. M. Mickle M.A. | Co-Founder and Chief Development Officer |
| R. LaDuane Clifton CPA | Chief Financial Officer, Secretary and Treasurer |
| Joshua M. Schafer M.B.A. | Chief Commercial Officer and Executive Vice President of Business Development |
| Dr. Sven Guenther Ph.D. | Chief Scientific Officer |
| Nichol L. Ochsner | Vice President of Investor Relations and Corporate Communications |
| Dr. Christopher M. Lauderback Ph.D. | Senior Vice President of Manufacturing |
| Dr. Rene A. Braeckman Ph.D. | Senior Vice President of Clinical Development |
| Dr. Daniel Gallo Ph.D. | Senior Vice President of Medical Affairs and Advocacy |
| Dr. Adrian Quartel FFPM, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 424B3 | Prospectus |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 8, 2024 | EFFECT | Notice of Effectiveness |
| Apr 8, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 2, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |